top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-NDG MHC I/II DKO mice plus
Strain Name 

NOD.CB17-Prkdcscid Il2rgtm1Bcgen B2mtm1Bcgen Fcgrttm1(B2m/Fcgrt)Bcgen H2-Ab1tm1Bcgen/Bcgen


Common Name 

B-NDG MHC I/II DKO mice plus

Background B-NDG mice Catalog number 111895
Aliases 

H2-Ab1: AI845868, Abeta, H-2Ab, H2-Ab, I-Abeta, IAb, Ia-2, Ia2, Rmcs1;
B2m: Ly-m11, beta2-m, beta2m;
Fcgrt: FcRn

Protein expression analysis


from clipboard


Strain specific H-2Kb/H-2Db (MHC-I) and I-Ak (MHC-II) expression analysis in B-NDG mice, B-NDG B2m KO plus mice and B-NDG MHC I/II DKO mice plus by flow cytometry.  Splenocytes were collected from the three mice and analyzed by flow cytometry. Mouse H-2Kb/H-2Db was only detectable in B-NDG mice but not in B-NDG B2m KO plus mice and B-NDG MHC I/II DKO mice plus. Mouse I-Ak was only detectable in B-NDG mice and B-NDG B2m KO plus mice but not in B-NDG MHC I/II DKO mice plus.


Frequency of leukocyte subpopulations in spleen,blood and bone marrow 


from clipboard

Frequency of leukocyte subpopulations in spleen, blood and bone marrow by flow cytometry. Blood, spleen and bone marrow were collected from B-NDG mice and B-NDG MHC I/II DKO mice plus (male, 9-week-old, n=3). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells, B cells and NK cells were not detectable in all tissues of B-NDG mice and B-NDG MHC I/II DKO mice plus. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***p < 0.001. 


Significantly reduced severity of GvHD induced with human PBMC engraftment in B-NDG MHC I/II DKO mice plus

from clipboard


Comparison of the severity of GvHD induced with human PBMC engraftment in B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus. Five weeks old of female B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus were respectively engrafted intravenously with human PBMCs (5 × 106) from three healthy donors (Donor 1-3) on day 0 (n=5).  A. Survival rates of the mice were analyzed with Kaplan Meier survival curves. B. Body weight changes. C. Clinical signs of GvHD were scored twice a week. Results showed that MHC I/II double knocked-out in B-NDG MHC I/II DKO mice plus can significantly extend the life span and reduced the GvHD induced with human PBMC engraftment when compared that in B-NDG mice or in B-NDG B2m KO mice plus. Therefore B-NDG MHC I/II DKO mice plus are more suitable mouse model for human PBMC engraftment into the immunodeficient mice. Values were expressed as mean ± SEM. 

Significantly reduced severity of GvHD induced with human PBMC engraftment in B-NDG MHC I/II DKO mice plus

from clipboard


Comparison of the peripheral blood leukocyte subpopulations in B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus after human PBMC engraftment. Five weeks old of female B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus were respectively engrafted intravenously with human PBMCs (5 × 106) from three healthy donors (Donor 1-3) on day 0 (n=5). Blood was collected weekly after engraftment of human PBMC for flow cytometric analysis. The reconstitution levels of all the leukocytes analyzed were similar among the three mice. 


Absolute number of reconstituted human immune cells  


from clipboard

Comparison of reconstitution levels of human PBMCs among B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus. Five-week-old female B-NDG mice, B-NDG B2m KO mice plus and B-NDG MHC I/II DKO mice plus were irradiated with 1.0 Gy and then engrafted intravenously with human PBMCs (5×106) from three healthy donors (Donor 1-3) on day 0 (n=6). Peripheral blood was taken weekly to analyze the reconstitution level of human immune cells. The experiment was ended 90 days after reconstitution. The results showed that regardless of which donor derived PBMCs were implanted, various types of human T cells could be reconstituted in B-NDG MHC I/II DKO mice plus. However, the numbers of all reconstituted cells in B-NDG MHC I/II DKO mice plus were lower than those in B-NDG mice and B-NDG B2m KO plus mice. Donor 3 has the most severe GvHD, and its human T cells and CD4 + T cells reconstitute the largest number.

A successful human PBMCs engrafted mouse model that can extend the window period of experiments

from clipboard

B-NDG MHC I/II DKO mice plus has a long life span and reduced severity of GvHD when engrafted with human PBMCs. B-NDG MHC I/II DKO mice plus were engrafted intravenously with human PBMCs (1×107) on day 0 (n=6). Survival rates of the mice were analyzed with Kaplan Meier survival curves. Body weight was measured twice a week. Clinical signs of GvHD were scored once a week. Euthanasia was implemented when the body weight decreased more than 20%. Meanwhile, the GvHD score of the mouse was recorded as 10. Results showed that all the mice can live up to 96 days. During this period, apart from weight loss, there were no other obvious symptoms of GvHD. Values were expressed as mean ± SEM. 

Frequency of reconstituted human immune cells  

from clipboard

Human PBMCs were successfully reconstituted in B-NDG MHC I/II DKO mice plus. B-NDG MHC I/II DKO mice plus were engrafted intravenously with human PBMCs (1×107) on day 0 (n=6). Peripheral blood was taken weekly to analyze the reconstitution level of human immune cells. The experiment was ended 112 days (16 weeks) after engraftment. A. Frequency of reconstituted human immune cells; B. Absolute cell number of reconstituted human immune cells. The results showed that two weeks after the reconstitution of human PBMCs in B-NDG MHC I/II DKO mice plus, the frequency and absolute cell number of CD45+ cells in peripheral blood began to increase, and a relatively stable level of reconstitution was maintained until the end point at 16 week. The frequency of reconstituted human T cells exceeded 90% from two weeks and continued to rise, eventually reaching nearly 100%. Reconstituted human T cells include CD4+T cells, CD8+T cells and Tregs. A small amount of DCs can also be detected. Human PD-1 is widely expressed on CD4+T cells and CD8+T cells. This indicates that B-NDG MHC I/II DKO mice plus is a powerful immunodeficient mouse model for reconstitution of the human immune system using human PBMCs.